Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PTC Therapeutics, Inc. - Common Stock
(NQ:
PTCT
)
73.69
+9.20 (+14.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PTC Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
↗
December 02, 2024
The deal focuses on the company's treatment for Huntington's disease.
Via
Investor's Business Daily
PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
↗
November 27, 2024
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including Huntington's and PKU programs.
Via
Benzinga
FDA Grants Conditional Approval For PTC Therapeutics' Gene Therapy As First Ever With Direct Administration In Brain
↗
November 14, 2024
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC deficiency treatment.
Via
Benzinga
Earnings Preview For PTC Therapeutics
↗
November 06, 2024
Via
Benzinga
3 Top Stocks That Could Still Rocket Higher in 2024
↗
October 04, 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
Via
The Motley Fool
PTC Therapeutics Stock Earns RS Rating Upgrade To 83
↗
August 19, 2024
The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.
Via
Investor's Business Daily
Recap: PTC Therapeutics Q4 Earnings
↗
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
↗
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Preview: PTC Therapeutics
↗
February 28, 2024
Via
Benzinga
PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 10, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
June 28, 2024
Via
Benzinga
PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again
↗
June 28, 2024
The company plans to ask for another re-examination for its drug in Europe.
Via
Investor's Business Daily
Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday
↗
June 21, 2024
Via
Benzinga
PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder
↗
June 20, 2024
PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
↗
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
May 20, 2024
Via
Benzinga
European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance
↗
May 20, 2024
PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available...
Via
Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
↗
May 20, 2024
Via
Benzinga
PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day'
↗
May 20, 2024
The EC is asking its committee to reexamine its decision on Translarna.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 20, 2024
Via
Benzinga
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
↗
May 01, 2024
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
Via
Investor's Business Daily
PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
April 25, 2024
PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
↗
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
↗
February 11, 2024
Bad news for one player does not always equal good news for another.
Via
The Motley Fool
PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug
↗
January 26, 2024
European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market.
Via
Investor's Business Daily
PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe
↗
January 26, 2024
CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 26, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
January 25, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
